在刚刚过去的2025年,我国创新药迎来丰收,共有76个创新药获批上市,同比增超58%;同时,创新药对外授权交易超过150起,交易总金额超过1300亿美元。展望2026年,有机构表示,我国医药生物行业将正式步入创新药大时代。该机构认为,2026年创新药将逐渐占据我国医药生物行业的主要地位,医保商保的互补结合将长期打开支付空间的天花板,创新药将持续蓬勃发展。据悉,2025年底推出的首版商业健康保险创新...
Source Link在刚刚过去的2025年,我国创新药迎来丰收,共有76个创新药获批上市,同比增超58%;同时,创新药对外授权交易超过150起,交易总金额超过1300亿美元。展望2026年,有机构表示,我国医药生物行业将正式步入创新药大时代。该机构认为,2026年创新药将逐渐占据我国医药生物行业的主要地位,医保商保的互补结合将长期打开支付空间的天花板,创新药将持续蓬勃发展。据悉,2025年底推出的首版商业健康保险创新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.